Baxter (NYSE: BAX) reported Q2 EPS of $0.80, $0.06 better than the analyst estimate of $0.74. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $3.11 billion.

“As markets worldwide continue to cope with the effects from the COVID-19 pandemic, Baxter’s second quarter performance reflects the diversity and durability of our lifesaving portfolio combined with the breadth of our geographic reach,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “Our drive to innovate, the essential nature of our product lines and the momentum of our transformation are all critical factors in our effort to improve performance and extend our impact. I am looking forward to our upcoming Investor Conference in September, where we will showcase our strategies to help drive incremental value for patients, clinicians, investors and the many other stakeholders we serve.”

GUIDANCE:

Baxter sees FY2021 EPS of $3.49-$3.55, versus the consensus of $3.51.

For earnings history and earnings-related data on Baxter (BAX) click here.